US Presidential Debates Begin: Pharma Is Favorite Villain – But Issues Focus Elsewhere
Executive Summary
To no one’s surprise, attacks on the drug industry are a recurring and unifying theme for the Democratic Presidential candidates as they enter the debate cycle. But rhetoric aside, the health policy proposals getting the most airtime are more threatening for other sectors.
You may also be interested in...
Trump’s Maximum Pressure Campaign On US Drug Pricing
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says
Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.
Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation
The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.